scholarly journals A brief review and case report of urothelial carcinoma and metachronous leiomyosarcoma of the bladder at the same anatomic region

2021 ◽  
pp. 101931
Author(s):  
Yajie Li ◽  
Hang Zhang ◽  
Zhenwei Wang ◽  
Hongbin Shi ◽  
Lihong Nie ◽  
...  
2021 ◽  
pp. 247412642110136
Author(s):  
Diana H. Kim ◽  
Tian Xia ◽  
Peter Bracha ◽  
Brian L. VanderBeek

Purpose: This report aims to describe a case of bilateral, multifocal neurosensory retinal detachments that developed during erdafitinib therapy for metastatic urothelial carcinoma. Methods: A case report with color fundus imaging and spectral-domain optical coherence tomography imaging is presented. Results: A 50-year-old man with metastatic urothelial carcinoma had an unremarkable baseline ophthalmic examination prior to starting erdafitinib. At 3-month follow up, an examination revealed bilateral, multifocal retinal detachments. Because the patient was asymptomatic and erdafitinib was the only drug to which his tumor had responded, he was kept on the medication with close ophthalmic monitoring. Conclusions: Erdafitinib, a fibroblast growth factor receptor inhibitor, can cause bilateral, multifocal retinal detachments. Continuation of erdafitinib may be considered in patients without significant visual impairment when the overall benefit of the medication appears to outweigh the risks.


2021 ◽  
Vol 37 ◽  
pp. 101618
Author(s):  
Masahiro Katsui ◽  
Tomohiro Iwasawa ◽  
Sotaro Kitaoka ◽  
Orikasa Hideki ◽  
Seiya Hattori ◽  
...  

2020 ◽  
Author(s):  
Nadia Espejo-Herrera ◽  
Enric Condom Mundó

Abstract Background: Yolk sac tumor is a germ cell neoplasm that arises predominantly in the gonads, but can also derive from somatic neoplasms in extragonadal locations. These cases have been denominated recently as “somatically derived Yolk sac tumors”, and have been documented in several locations, although reports from the urinary tract are scarce. To our knowledge, this is the first report of a Yolk sac tumor derived from urothelial carcinoma. Case presentation: We present a unique case of a 76-year-old man with a recurrent urinary bladder tumor, initially interpreted as a high grade urothelial carcinoma with glandular differentiation. In the recurrent tumor, diverse histological patterns were identified, including glandular, hepatoid and sarcomatoid. This tumor showed positivity for AFP, GLP3 and SALL4, and negativity for CK7 and EMA. Fluorescent in situ hybridization study showed a polysomic pattern of chromosome 12. All these findings led to the final diagnosis of a Yolk sac tumor derived from urothelial carcinoma. Conclusions: Somatically derived Yolk Sac tumors should be considered in the differential diagnosis of a high grade urothelial carcinoma, particularly when glandular and other unusual patterns are observed. Key words: Yolk sac tumor, somatically derived, urothelial carcinoma, urinary bladder, case report.


Author(s):  
Alexander de J. Rafaelano M. ◽  
Junior J. Araiza Navarro ◽  
María Isabel Tolentino Sosa ◽  
Fernando López Reyes ◽  
Marlene De la Peña Gutiérrez

The urothelial carcinoma is the most common type of bladder cancer, comprising approximately 90% of cases in the United States. The most common symptom of bladder cancer is macroscopic hematuria, increased urinary frequency, urgency, or irritative symptoms may occur. Generally, occurs in elderly people, about 9 out of 10 people are over 55 years old, with the average age at diagnosis of 73 years. Males are more likely than women to have this neoplasm with a probability of 1 in 27 (for women the probability is 1 in 89). Most bladder cancers begin in the inner layer, also called the urothelium or transitional epithelium. As it advances, it invades the layers of the bladder and can invade adjacent structures, often metastasizing to distant lymph nodes, bones, lungs or the liver. Among the cancers that originate in the bladder authors have: Urothelial carcinoma (transitional cell carcinoma), squamous cell carcinoma, adenocarcinoma, small cell carcinoma, sarcoma. Hematuria occurs in the majority of patients with urothelial carcinoma. Symptoms such as dysuria, frequency, urgency and pain may also occur, or it may also be asymptomatic.  In this case report, an atypical presentation of bladder cancer is shown, simulating the symptomatology of a Hyperactive Bladder Syndrome.


2019 ◽  
Vol 18 (3) ◽  
pp. e2469
Author(s):  
F. Ekren ◽  
G.E. Eker ◽  
M. Esen ◽  
A. Caglayan ◽  
O. Erdogan ◽  
...  

2016 ◽  
Vol 12 (2) ◽  
pp. 1129-1131 ◽  
Author(s):  
Tao Li ◽  
Liang Gao ◽  
Weilu Wu ◽  
Peng Chen ◽  
Siyuan Bu ◽  
...  

2014 ◽  
Vol 8 (1) ◽  
Author(s):  
Virginia M Knez ◽  
Willis Barrow ◽  
M Scott Lucia ◽  
Shandra Wilson ◽  
Francisco G La Rosa

Sign in / Sign up

Export Citation Format

Share Document